Olaparib (Lynparza) for metastatic castration-resistant prostate cancer - Details


( Last Updated : May 6, 2021)
Generic Name:
Olaparib
Project Status:
Active
Therapeutic Area:
metastatic castration-resistant prostate cancer (mCRPC)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
PC0223-000
NOC Date:

Details


Strength:
100 mg and 150 mg
Tumour Type:
Genitourinary
Indications:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Funding Request:
As monotherapy for the treatment of adult patients with mCRPC and deleterious or suspected deleterious germline and/or somatic mutations in the HRR genes BRCA or ATM who have progressed following prior treatment with a NHA.
Review Status:
Notification to Implement Issued
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.